Medicare drug price negotiation program under the IRA is no longer theoretical, it is operational and already reshaping the Medicare drug landscape. This roundtable will examine how the first year of negotiated pricing in Medicare Part D is playing out, including what has worked as intended, what has surprised stakeholders, and where operational and financial challenges remain as well as look at the Part D impact in 2028.
Discuss challenges to drug reimbursement benchmarks such as ASP, AWP, and WAC with the Medicare drug price negotiation program.
